Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $108.00

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price hoisted by investment analysts at Oppenheimer from $96.00 to $108.00 in a research report issued on Friday, The Fly reports. Oppenheimer’s price target would indicate a potential upside of 22.78% from the stock’s current price.

APLS has been the topic of several other research reports. Stifel Nicolaus raised their target price on Apellis Pharmaceuticals from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. Citigroup boosted their target price on Apellis Pharmaceuticals from $88.00 to $106.00 in a research note on Monday, May 8th. The Goldman Sachs Group upped their price objective on Apellis Pharmaceuticals from $124.00 to $141.00 and gave the stock a “buy” rating in a research report on Friday, April 14th. Wells Fargo & Company boosted their target price on Apellis Pharmaceuticals from $55.00 to $76.00 in a report on Friday, May 5th. Finally, HC Wainwright increased their target price on Apellis Pharmaceuticals from $87.00 to $100.00 in a research note on Friday, May 5th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $90.93.

Apellis Pharmaceuticals Trading Down 0.7 %

Apellis Pharmaceuticals stock opened at $87.96 on Friday. The business has a 50-day simple moving average of $75.78 and a two-hundred day simple moving average of $60.77. The company has a market cap of $9.79 billion, a P/E ratio of -14.03 and a beta of 1.23. Apellis Pharmaceuticals has a 52-week low of $37.36 and a 52-week high of $94.45. The company has a quick ratio of 3.78, a current ratio of 4.29 and a debt-to-equity ratio of 0.55.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.14). The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $26.10 million. Apellis Pharmaceuticals had a negative return on equity of 255.36% and a negative net margin of 652.50%. The firm’s revenue for the quarter was up 211.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.42) earnings per share. Analysts predict that Apellis Pharmaceuticals will post -5.22 EPS for the current year.

Insider Buying and Selling

In other news, CEO Cedric Francois sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $62.74, for a total value of $1,882,200.00. Following the completion of the sale, the chief executive officer now directly owns 1,144,591 shares in the company, valued at approximately $71,811,639.34. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Jeffrey Eisele sold 1,646 shares of the company’s stock in a transaction on Thursday, February 23rd. The shares were sold at an average price of $68.76, for a total value of $113,178.96. Following the completion of the transaction, the insider now directly owns 53,883 shares in the company, valued at $3,704,995.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cedric Francois sold 30,000 shares of the business’s stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $62.74, for a total transaction of $1,882,200.00. Following the completion of the sale, the chief executive officer now directly owns 1,144,591 shares of the company’s stock, valued at $71,811,639.34. The disclosure for this sale can be found here. Insiders sold a total of 110,646 shares of company stock valued at $8,275,584 in the last three months. Insiders own 8.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. lifted its stake in Apellis Pharmaceuticals by 6.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock worth $167,000 after purchasing an additional 209 shares in the last quarter. Amalgamated Bank lifted its position in Apellis Pharmaceuticals by 1.5% during the fourth quarter. Amalgamated Bank now owns 15,403 shares of the company’s stock valued at $796,000 after acquiring an additional 231 shares during the last quarter. Neuberger Berman Group LLC increased its stake in Apellis Pharmaceuticals by 0.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 44,334 shares of the company’s stock valued at $3,028,000 after purchasing an additional 290 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Apellis Pharmaceuticals by 2.6% in the fourth quarter. Handelsbanken Fonder AB now owns 12,000 shares of the company’s stock worth $621,000 after acquiring an additional 300 shares during the period. Finally, Profund Advisors LLC grew its position in Apellis Pharmaceuticals by 2.5% during the fourth quarter. Profund Advisors LLC now owns 12,722 shares of the company’s stock valued at $658,000 after buying an additional 315 shares during the period. Institutional investors own 87.26% of the company’s stock.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.